Introduction to TKI-Associated Renal Toxicity

Tyrosine kinase inhibitors (TKIs) have revolutionized the management of radioiodine-refractory differentiated thyroid cancer (DTC). However, clinicians must remain vigilant about TKI induced proteinuria, a significant adverse event linked to VEGF pathway inhibition. While these agents like lenvatinib, sorafenib, and cabozantinib offer substantial oncological benefits, they frequently impact renal function through complex mechanisms.

The Pathophysiology of TKI Induced Proteinuria

The underlying mechanism of renal damage is multifactorial. VEGF inhibition disrupts the delicate crosstalk between endothelial cells and podocytes. This disruption often leads to structural changes such as focal segmental glomerulosclerosis or minimal change disease. Furthermore, systemic hypertension induced by these drugs often exacerbates glomerular injury. Consequently, patients may present with varying degrees of protein loss, ranging from mild asymptomatic cases to full-blown nephrotic syndrome.

Monitoring and Clinical Management

Regular monitoring is the cornerstone of safe TKI administration. Experts recommend performing baseline urinalysis followed by regular protein-to-creatinine ratio (UPCR) assessments or 24-hour urine collections. If TKI induced proteinuria reaches grade 2 or higher, clinicians should consider immediate intervention. Timely dose adjustments or temporary treatment pauses often facilitate the partial or full reversibility of renal damage. In some instances, switching to a TKI with a different nephrotoxic profile, such as moving from lenvatinib to sorafenib, may maintain disease control while reducing renal risk.

The Role of Multidisciplinary Care

Effective management requires a collaborative approach between oncologists, endocrinologists, and nephrologists. Early detection of rising protein levels allows for proactive adjustments before irreversible damage occurs. While switching agents is a feasible strategy, it requires cautious implementation based on the individual patient's oncological response and renal reserve.

FAQs on TKI Induced Proteinuria

Is TKI-induced proteinuria permanent?

No, renal damage is often reversible. If clinicians detect the issue early and implement dose reductions or treatment pauses, protein levels typically return to baseline. However, delayed intervention may lead to permanent glomerular scarring.

Which TKI is most associated with nephrotic syndrome?

Lenvatinib often shows a higher incidence of high-grade proteinuria compared to sorafenib in clinical trials. Nevertheless, direct comparisons are difficult due to differences in patient populations and dosing schedules.

Should I refer a patient to a nephrologist immediately?

Yes, early involvement of a nephrologist is beneficial, especially if the patient develops nephrotic-range proteinuria (over 3.5g/day) or shows signs of declining glomerular filtration rate (GFR).

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.

References

Van Damme M et al. TKI-associated proteinuria and nephrotic syndrome: a narrative review with clinical illustration in radio-iodine-refractory thyroid cancer. Acta Clin Belg. 2026 Jun 06. doi: 10.1080/17843286.2026.2680287. PMID: 42251484.

Kawano K et al. Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer. Int J Urol. 2024 May 15. doi: 10.1111/iju.15482.

Saba NF et al. Managing MKI-Induced Proteinuria in Advanced Thyroid Cancer. ASCO Daily News. 2024 Mar 20.